Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features. The aim of this study is to evaluate how PR‐PFD performs on metabolic functions, and provide...

Full description

Saved in:
Bibliographic Details
Published in:Hepatol Commun
Main Authors: Sandoval‐Rodriguez, Ana, Monroy‐Ramirez, Hugo Christian, Meza‐Rios, Alejandra, Garcia‐Bañuelos, Jesus, Vera‐Cruz, Jose, Gutiérrez‐Cuevas, Jorge, Silva‐Gomez, Jorge, Staels, Bart, Dominguez‐Rosales, Jose, Galicia‐Moreno, Marina, Vazquez‐Del Mercado, Monica, Navarro‐Partida, Jose, Santos‐Garcia, Arturo, Armendariz‐Borunda, Juan
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049672/
https://ncbi.nlm.nih.gov/pubmed/32140659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1474
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items